Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis
This study highlights the potential benefit of apremilast for the treatment of ICI-PsO, both de novo and PsO flare, with less of an apparent benefit for ICI-PsA. Thirty percent of patients in the whole group had to discontinue apremilast due to intolerance. Apremilast may be an attractive therapeutic option for either condition given that it is not immunosuppressive, but further prospective observational studies with larger patient numbers are needed.
Authors
- Jeffrey A. Sparks (ORCID: https://orcid.org/0000-0002-5556-4618)
- Ke Ge (ORCID: https://orcid.org/0000-0002-7436-3897)
- Kaitlin R. McCarter
- Nilasha Ghosh (ORCID: https://orcid.org/0000-0002-8799-9309)
- Anne R. Bass (ORCID: https://orcid.org/0000-0002-3225-8351)
- Pankti Reid (ORCID: https://orcid.org/0000-0002-7645-0919)
Institutions
- Hospital for Special Surgery (US)
- Brigham and Women's Hospital (US)
- Cornell University (US)
- University of Chicago (US)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1002/acr.25604
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Arthritis Foundation
- Rheumatology Research Foundation
- Gordon and Llura Gund Foundation
- National Heart, Lung, and Blood Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases